Subscribe To
Zynerba pharmaceuticals announces positive long-term data from phase 2 inspire trial at annual meeting of the american college of neuropsychopharmacology
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) said it has presented a poster at the 61st annual meeting of the American College of Neuropsychopharmacolog...
December 5, 2022, 8:36 am